Cytokinetics, Incorporated

Cytokinetics, Incorporated

58.27
CHF
-3.87
(-6.22%)
-5.80EPS
Nov 04Next Earn

Important Dates

Cytokinetics, Incorporated's next confirmed earnings release is scheduled for November 4, 2026.

Earnings Date11/4/2026

Share Statistics

As of June 30, 2026, Cytokinetics, Incorporated has 138.76M shares outstanding.

Shares Outstanding138.76M

Financial Position

As of June 30, 2026, Cytokinetics, Incorporated maintains a current ratio of 6.66, meaning it holds 6.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -732.36, indicating conservative leverage, while an interest coverage ratio of -5.57 demonstrates limited ability to service its debt obligations.

Current Ratio6.66
Quick Ratio6.56
Debt / Equity-732.36
Debt / EBITDA-1.83
Interest Coverage-5.57

Financial Efficiency

CHF

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -56.76, reflecting losses generated across the asset base. The company generates approximately 86,874.62 in revenue per employee across its workforce of 629.25, a quick read on workforce productivity versus industry peers.

Return on Assets (ROA)-56.76
Revenue Per Employee86,874.62
Employee Count629.25

Stock Price Statistics

As of the close on August 31, 2026, Cytokinetics, Incorporated's stock has gained approximately 113.56% over the past 52 weeks.

52-Week Price Change113.56%

Income Statement

CHF

Over the twelve months ended June 30, 2026, Cytokinetics, Incorporated generated 54.67M in revenue and converted that into -722.20M in net income, yielding earnings per share of -5.80. EBITDA reached -561.73M, while operating income came in at -571.87M.

Revenue54.67M
Gross Profit-116.41M
Operating Income-571.87M
Pretax Income-722.20M
Net Income-722.20M
EBITDA-561.73M
EBIT-571.87M
Earnings Per Share (EPS)-5.80

Balance Sheet

CHF

As of June 30, 2026, Cytokinetics, Incorporated holds 941.68M in cash and equivalents against 1.03B in total debt, resulting in a net debt position of 720.44M. Total book value stands at -140.15M, with working capital of 829.69M providing operational flexibility.

Cash & Cash Equivalents941.68M
Total Debt1.03B
Net Debt720.44M
Equity (Book Value)-140.15M
Book Value Per Share-1.01
Working Capital829.69M

Cash Flow

CHF

Cytokinetics, Incorporated produced -448.71M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -20.41M in capital expenditures, free cash flow totaled -469.12M - equivalent to -3.77 per share.

Operating Cash Flow-448.71M
Capital Expenditures-20.41M
Free Cash Flow-469.12M
FCF Per Share-3.77

Margins

Over the twelve months ended June 30, 2026, Cytokinetics, Incorporated posted a gross margin of -212.95, reflecting its pricing power and cost economics. The operating margin of -1,046.12 and net profit margin of -1,321.12 provide insight into operational efficiency.

Gross Margin-212.95
Operating Margin-1,046.12
Pretax Margin-1,321.12
Profit Margin-1,321.12
EBITDA Margin-1,027.58

Stock Splits

Cytokinetics, Incorporated's most recent stock split took place on June 25, 2013 with a 6:1 split ratio.

Last Split Date6/25/2013
Split Ratio6:1